RxDoctor Payments Data

Timothy Siegrist, MD

Urology · Middletown, CTNPI 1720279946

Payments from drug & device makers

$2,663in general payments, 2019–2025

Across 54 payments — averaging $49.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neotract Inc.$1K
  • C. R. Bard, Inc. & Subsidiaries$454
  • Procept Biorobotics Corporation$281
  • Pfizer$181
  • Ferring Pharmaceuticals Inc.$125
  • Astellas Pharma US Inc$124
  • plus $440 from 9 others

What the payments were for

  • Travel & lodging$85932%
  • Food & beverage$1,65862%
  • Education$1476%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,663 in reported general payments places this provider in the 55th percentile of 156 urology providers in Connecticut.

See all urology providers in Connecticut

Medicare billing

Part B allowed, 2024
$177,232
Medicare patients
395
Services billed
8,509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron139$118,203
MyrbetriqMirabegron128$99,909
Mirabegron ErMirabegron35$17,484
Tamsulosin Hcl929$12,009
Testosterone35$9,899
Finasteride366$5,869
Methenamine Hippurate47$4,326
Potassium Citrate ErPotassium Citrate53$2,457
Testosterone Cypionate53$1,766
Alfuzosin Hcl ErAlfuzosin Hcl72$1,715
Tolterodine Tartrate ErTolterodine Tartrate25$1,483
Trospium Chloride21$1,341
Oxybutynin Chloride ErOxybutynin Chloride71$1,241
Tadalafil28$985
Silodosin12$969

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$29$118,203139 claims
Astellas Pharma US IncMyrbetriq$124$99,909128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 156 urology providers in Connecticut.

Other urology in Middletown

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →